Glial scars that consist predominantly of reactive astrocytes create a major barrier to neuronal regeneration after traumatic brain injury (TBI). In experimental TBI, Eph receptors and their ephrin ligands are upregulated on reactive astrocytes at injury sites and inhibit axonal regeneration, but very little is known about Eph receptors in the human brain after TBI. A better understanding of the functions of glial cells and their interactions with inflammatory cells and injured axons will allow the development of treatment strategies that may promote regeneration. We analyzed EphA4 expression and activation in postmortem brain tissue from 19 patients who died after acute closed head injury and had evidence of diffuse axonal injury and 8 controls. We also examined downstream pathways that are mediated by EphA4 in human astrocyte cell cultures. Our results indicate that, after TBI in humans, EphA4 expression is upregulated and is associated with reactive astrocytes. The expression was increased shortly after the injury and remained activated for several days. EphA4 activation induced under inflammatory conditions in vitro was inhibited using unclustered EphA4 ligand. These results suggest that blocking EphA4 activation may represent a therapeutic approach for TBI and other types of brain injuries in humans.
INTRODUCTION
Understanding the functions of glial cells and their interactions with inflammatory cells and injured axons may allow the development of treatment strategies that can promote regeneration after brain injury. The healing response to injuries of the mature brain terminates with the formation of a tight barrier, the glial scar, which consists predominantly of reactive astrocytes. Glial scars have long been considered to be a major impediment to regeneration of damaged axons (1, 2) , and reactive gliosis is generally regarded as detrimental to neural tissue repair and functional restoration. This notion has been further consolidated by the discovery that the scar tissue is highly enriched with molecules that are inhibitory to axon regeneration and remodeling such as Eph receptors and their ephrin ligands (3) .
Eph and ephrin molecules are membrane-bound cell surface proteins and form the largest family of tyrosine kinase receptors. Ephs and ephrins are upregulated and reexpressed after brain and spinal cord injury (SCI) and in diseases in which they inhibit axonal regeneration and restoration of function (4) . EphA4 is upregulated after experimental SCI and mediates creation of the glial scar at the injury site (5Y8). Conversely, mice lacking EphA4 showed substantially decreased astrocytic gliosis after traumatic injury, concomitant with extensive axonal regeneration and recovery of function (6) . In one of the few studies investigating the role of these molecules in the primate brain, we have shown that EphA4 expression on astrocytes is increased around the site after cortical lesion (9) . Upregulation of the Ephs and ephrins has also been reported on reactive astrocytes in demyelinated lesions in patients with multiple sclerosis (MS) (10) .
It is not clear at present whether upregulation and activation of the Eph/ephrin molecules leads to a cascade of events that regulates the inflammatory response after injury and then leads to the formation of the glial scar or whether the inflammatory responses lead to an increase of signaling activity by Ephs and ephrins. Previous studies have highlighted a potential therapeutic strategy for CNS injuries in animal models by blocking Eph/ephrin signaling (5, 11Y15). In particular, these studies have used unclustered ephrins that antagonize Eph-ephrin interactions (16, 17) ; however, very little is known about the role of Ephs and ephrins in the human brain, particularly after traumatic brain injury (TBI). Here, we analyzed EphA4 expression and activation in postmortem brain tissue from patients who died after acute closed head injury with clear evidence of diffuse axonal injury. In addition, we examined effects of inflammatory cytokines on EphA4 activation in human astrocytes in vitro and whether blocking EphA4 receptor on these cells would reduce its direct and indirect activation. Brain samples from 19 individuals who died after closed head injury were obtained from the Australian Neurotrauma Tissue and Fluid Bank. We used samples from the same cohort of patients in 2 previous studies (18, 19) . Cases were between 17 and 78 years (mean, 47 years) and had various causes of TBI (Table) . All had a closed head injury with clear evidence of diffuse axonal injury and no apparent subdural hematoma. The postmortem intervals varied between 40 and 129 hours (mean, 81 hours). The brain region analyzed in each case was located within 1 cm of the injured tissue identified macroscopically by a neuropathologist (C.M.). A second brain region was also analyzed for cases with a survival time of more than 6 hours; this was located in the contralateral brain hemisphere at the same locus as in the ipsilateral hemisphere and where no macroscopic damage was detected. Control brain samples of 8 individuals, aged between 19 and 78 years (mean, 41 years), without brain injury or other neuropathologic abnormalities were obtained from the National Neural Tissue Resource Centre of Australia. Clinical information and epidemiological data on all patients are listed in the Table. Immunohistochemistry Seven-micrometer-thick paraffin-embedded sections were processed to determine the expression and localization of EphA4 as previously described (18, 19) . Briefly, paraffin sections were deparaffinized, rehydrated, microwave treated for antigen retrieval, washed 3 times with phosphate-buffered saline (PBS), and blocked for 1 hour at room temperature (RT) in blocking solution containing 5% normal goat serum, 1% bovine serum albumin, and 0.1% Tween-20 in PBS. Primary antibody was added in blocking solution, and sections were incubated overnight at 4-C. The primary antibodies were rabbit polyclonal anti-EphA4 (1:300; prepared against a peptide corresponding to amino acids 938Y953 of the intracellular SAM domain of EphA4, obtained from Dr. J. Coonan, Walter and 
MATERIALS AND METHODS

Human Postmortem Brain Tissue
EphA4 Expression Density on GFAP-Expressing Cells
EphA4 immunofluorescence density was measured on GFAP-expressing astrocytes using ImageJ software (Wayne Rasband, National Institutes of Health, Bethesda, MD) in control uninjured brain (n = 4), in brains of individuals who died within 1 hour of the injury (n = 6; Table) , and in brains of individuals who died more than 1 day after the injury (n = 6). Results are presented as mean T SE.
Western Blot and Immunoprecipitation of Brain Tissue
Fresh, frozen cortical samples (100 mg) were homogenized using an ultra-turrax (Ika, Wilmington, NC) in 400 ml of lysis buffer (5 mmol/L Tris, 15 mmol/L NaCl, 1% Triton X-100). Homogenates were placed on ice and on a shaker for 90 minutes and then centrifuged at 2000 Â g for 10 minutes at 4-C. The supernatants were stored at j80-C until analysis. Total protein concentrations were determined using the Bradford method (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
To examine EphA4 phosphorylation, lysates of brain tissue were incubated for 2 hours with anti-mouse IgG agarose beads (Sigma, St. Louis, MO) conjugated with mouse anti-phosphotyrosine (1:50; Cell Signaling Technology). Immunoprecipitates were collected by centrifugation, washed 3 times with HNTG buffer (20 mmol/L HEPES pH 7.50, 150 mmol/L NaCl, 0.1% Triton X-100, 10% glycerol), resuspended in 35 Kl of loading buffer (200 mmol/L Tris-HCl pH 6.8, 8% SDS, 0.04% bromophenol blue, 40% glycerol, 400 mmol/L DLdithiothreitol), and heated for 5 minutes at 100-C. Proteins were resolved by SDS-PAGE using 8% to 16% gradient polyacrylamide gels (Gradipore, Frenchs Forest, NSW, Australia) in running buffer (25 
Microscopy
Sections were examined by bright field or fluorescence microscopy using an Axioplan Z1 epifluorescence microscope (Zeiss, Berlin, Germany). Photomicrographs (1,300 Â 1,030 dpi) were obtained with various Plan-Neofluar objectives (Zeiss) and acquired as digital images using an AxioCam (Zeiss) digital camera with AxioVision software (v. 4.4; Zeiss). To confirm colocalization of different proteins, optical sections of the samples were acquired on an Axioplan Z1 microscope equipped with the Apotome module and a 40Â objective, using AxioVision software.
Human Astrocyte Cultures
Cryopreserved passage no. 1 normal human astrocytes were purchased from ScienCell Research Laboratories (Carlsbad, CA; catalog no. 1800). Human astrocyte cultures were maintained in T75 tissue culture flasks precoated with poly-l-lysine (Nunc, Roskilde, Denmark) according to the supplier's instructions. Culture medium consisted of Dulbecco modified Eagle medium/F12 with 1% B27 and 0.5% N 2 supplements (both from Invitrogen), 10% fetal calf serum, 100 U/ml penicillin, and 100 Kg/ml streptomycin. The culture medium was replaced every third day. Confluent cultures of human astrocytes were passaged by trypsinization and replating at a seeding density of 5,000 cells/cm 2 . For analysis of EphA4 activation or inhibition, cells were trypsinized and replated into 10-cm Petri dishes (Nunc) at 1 Â 10 6 cells/plate. Cells were treated with 2 Kg/ml lipopolysaccharide (LPS; Sigma) and 3 ng/ml interferon-F (IFN-F; Roche) for 6, 16, 24, and 48 hours to induce astrocyte activation (20) . Immunoprecipitation was performed on cell lysates for analysis of EphA4 phosphorylation. For EphA4 phosphorylation by the soluble ligand clustered ephrinA5-Fc (cl-A5), cells were serum starved for 2 hours; ephrinA5-Fc (1.5 Kg/ml) was preclustered for 30 minutes with 150 ng/ml anti-human IgG (Vector Laboratories, Burlingame, CA) at RT. Clustered or unclustered ephrinA5-Fc (5 Kg/ml) was added to the astrocyte cultures at the indicated times. The cells were washed with cold PBS and lysed with lysis buffer (50 mmol/L HEPES pH 7.5, 150 mmol/L NaCl, 10% glycerol, 1% Triton X-100, 1 mmol/L FIGURE 1. EphA4 upregulation in the human brain after traumatic brain injury (TBI). (A, B) In control adult brain, there is EphA4 expression on neuronal cells in cortical Layers 2 and 3 (arrowheads) and on glial fibrillary acidic protein (GFAP)Ypositive astrocytes (arrow) (A) and on axons (red) along astrocyte processes (green) in the corpus callosum (BYBµ). (C) Some EphA4 expression is associated with a few astrocytes in the cortex around blood vessels (arrowhead) in control uninjured brain and very low to undetectable levels on other astrocytes in the gray matter (arrows). Less than 1 hour after TBI, EphA4 expression on astrocytes is similar to that in uninjured brain, whereas in the brains of individuals who died more than a day after injury, EphA4 immunoreactivity is upregulated on astrocytes expressing high levels of GFAP. (D) Quantitation of EphA4 density on GFAP-expressing astrocytes results are mean T SE. *, p G 0.001, 1-way analysis of variance. Scale bar = 50 Km.
EDTA, 1 mmol/L EGTA pH 8, 1.5 mmol/L MgCl 2 , 2 mmol/L phenylmethanesulfonyl fluoride, 0.2 mmol/L Na 3 VO 4 ) and a protein inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). The lysates were then clarified by centrifugation.
Rho GTPase activation was detected using the Rhotekin Rho Binding Domain assay (Upstate Biotechnology, Lake Placid, NY) according to the manufacturer's instructions. After treatment, the cells were washed once with ice-cold PBS and then lysed in 0.5 ml of Rho assay lysis buffer. Endogenous Rho-GTP was precipitated from the cell lysates at 4-C for 1 hour, using 30 mg of Rhotekin Rho Binding Domain agarose for each sample. The beads were pelleted by centrifuging at 14,000 Â g for 2 minutes, washed 3 times with the lysis buffer, and resuspended in 4Â loading buffer. The eluted protein samples were resolved on 12% SDS gels and analyzed by Western blot as been described above. Rho was detected using rabbit anti-Rho (1:1000; Cell Signaling). For mitogenactivated protein kinase (MAPK) activation, Western blots prepared using 20 Kg of total protein lysate were probed using rabbit antiYp-MAPK (1:1000; Cell Signaling). Membranes were stripped using glycine solution (0.2 mol/L, pH 2) at 60-C for 10 minutes followed by 3 washes in TBST (0.05 mol/L Tris pH 7.5, 0.15 mol/L NaCl, 0.5% Tween) and incubation with rabbit anti-MAPK (1:1000; Cell Signaling) for 2 hours at RT. Mouse antiYA-actin (1:10000; Sigma) was used as a protein loading control.
Cells were plated on 8-well chamber slides (Falcon BD, North Ryde, NSW, Australia) coated with poly-d-lysine (5 Â 10 3 cells/well) in growth medium. After 24 hours, the medium was replaced with fresh medium, and the cells were treated with LPS and IFN-F, cl-A5, or LPS, IFN-F, and monomeric ephrinA5-Fc for 7 days. After 7 days in culture, the cells were fixed with 4% paraformaldehyde for 10 minutes followed by permeabilization with chilled (j20-C) methanol and blocked with blocking solution (PBS containing 2% fetal calf serum, 2% goat serum) for 1 hour. Immunostaining was performed using mouse anti-GFAP (1:1000; Invitrogen) and rabbit antiKi67 (1:300; Thermo Scientific, Epsom, UK). Cells were incubated with primary antibodies for 2 hours, and the chamber slides were then washed 3 times in PBS. Cells were subsequently incubated with the secondary antibodies, goat anti-rabbit Alexa Fluor-488, and goat anti-mouse Alexa Fluor-594 (1:1000; Molecular Probes, Eugene, OR) for 1 hour at RT, washed 3 times in PBS, and mounted with Fluoromount (Dako, Carpinteria, CA). The nuclei of cells repopulating the scratched area were visualized by 4 ¶-6-diamidino-2-phenylindole (1:1000; Molecular Probes) staining. The number of astrocytes expressing 4 ¶-6-diamidino-2-phenylindole, GFAP, or/and Ki67 was counted per 0.035 mm 2 in arbitrarily chosen sample areas.
Statistics
Statistical analysis was performed using GraphPad Prism5 (La Jolla, CA). Kolmogorov-Smirnov test (with Lilliefors correction) was used to test data for normality within each group. One-way analysis of variance (ANOVA) was followed by multiple comparisons using the Tukey test to identify significant differences between TBI and control groups. Cultured astrocyte experiments are presented as mean T SE. Statistical significance was considered at p G 0.05.
RESULTS
EphA4 Is Expressed on Neuronal Cells in the Intact Brain
Immunofluorescence examination of the adult human brain showed sporadic EphA4 expression on neurons (determined morphologically) in Layers 2 and 3 of the frontal cortex and on axons aligned along astrocyte processes in the corpus callosum (Figs. 1AYBµ) . Localization of EphA4 in these areas has been shown previously in intact brain of animal models (21Y23) and in the human brain (10) . These results demonstrate that EphA4 expression is conserved among different species, including humans.
EphA4 Expression After TBI
In control brains, no EphA4 immunostaining was detected in the small numbers of astrocytes that were GFAP immunopositive (Figs. 1AYC) . Not all astrocytes in the control brain expressed EphA4, but expression was observed on astrocytes around blood vessels, suggesting a role in bloodbrain barrier maintenance. After brain injury, there were increased numbers of GFAP-positive reactive astrocytes (19) and EphA4 immunostaining markedly increased over time in the cortex (Fig. 1C) . This increase was quantified by density measurement on GFAP-expressing astrocytes. Within 1 hour after the injury, EphA4 expression on astrocytes was similar to that observed in control brains, that is, there were some astrocytes that expressed detectable EphA4, whereas others only expressed GFAP (Figs. 1C, D) . There was a significant increase of EphA4 expression on astrocytes in brains of individuals who died more than a day after the head injury (Fig. 1D) . In addition, a Pearson product-moment correlation was run to determine the relationship between EphA4 density and the postmortem interval or the age. This analysis showed that there was no significant relationship between EphA4 density and postmortem interval (r = 0.2707, p = 0.3105) or patient age (r = 0.0673, p = 0.2194).
EphA4 Activation Is Detected as Early as 8 Hours After TBI
To determine whether the increased expression of EphA4 detected on astrocytes was correlated with receptor activation, we measured levels of phosphorylated EphA4 in human brain homogenates. Phosphorylated EphA4 (p-EphA4) levels were significantly increased over time after TBI (p = 0.0003, 1-way ANOVA), as demonstrated by immunoprecipitation and Western blot analysis (Figs. 2A, B) . EphA4 was markedly activated in individuals who died more than 8 hours after brain injury versus controls and individuals who died less than 2 hours after TBI (p G 0.001, Tukey post hoc analysis). EphA4 activation was increased not only in the tissue taken from the injured region but also in the contralateral hemisphere, in the same locus of injury in the ipsilateral hemisphere, where no evidence of macroscopic abnormality was observed ( Fig. 2A) . The levels of activation were sustained over time with detection up to 93 hours after injury ( Fig. 2A) . Quantitation of EphA4 protein levels relative to A-actin revealed a statistical difference overall between the control and the TBI cohorts (p = 0.0328, 1-way ANOVA) but did not show specific differences between the groups after the Tukey multiple comparison test (Fig. 2B) . In addition, the levels of EphA4 activation in the controls and in the samples of individuals who died less than 2 hours after TBI were lower than the total levels of EphA4 expression in the tissue at the respective time points (Fig. 2B) .
Inflammatory Mediators Trigger EphA4 Activation in Human Astrocytes In Vitro
Both LPS and IFN-F induced EphA4 phosphorylation in a time-dependant manner from 6 to 48 hours compared with control untreated astrocytes (Fig. 3A) . Moreover, these molecules induced EphA4 phosphorylation as early as 2 hours after exposure, activating the Rho signaling pathway (Fig. 3B) . EphA4 activation was also induced in a time-dependent manner using cl-A5, which signaled through Rho and MAPK pathways (Fig. 3B) . Both treatments led to morphological changes in the cultured astrocytes. After 7 days, cells exhibit extended processes and stellate morphology compared with the flat and polygonal shape of untreated control cells (Fig. 3D) . Quantitation of cells that expressed both GFAP and Ki67 revealed that both LPS with IFN-F or cl-A5 alone led to a significant increase in GFAP-expressing cells versus untreated cultures (Fig. 3E) . In addition, both treatments resulted in a significant increase in the number of cells that express both GFAP and the proliferation marker Ki67 (Fig. 3F) , correlating with the increased total number of cells observed compared with controls (Fig. 3E ).
EphA4 Activation in Human Astrocytes Can Be Inhibited In Vitro
We next examined whether unclustered, monomeric ephrinA5-Fc (m-A5) could decrease EphA4 phosphorylation in basal conditions and in the presence of LPS and IFN-F. Unclustered ephrinA5-Fc abolished basal levels of EphA4 activation in the cultured cells and led to a decrease in downstream signaling, p-MAPK (Fig. 3C) , which mediates astrocyte proliferation and activation. Moreover, m-A5 reduced EphA4 activation in the presence of LPS and IFN-F, leading to decreased Rho-GTP levels that were increased by the inflammatory factors (Fig. 3B) . It also prevented the increase of GFAP expression, cell proliferation, and stellate morphology induced by LPS and IFN-F (Figs. 3D, F) . These data suggest that unclustered EphA ligands might reduce astrocytic EphA4 activation in vivo after TBI.
DISCUSSION
To our knowledge, this is the first study that confirms and extends previous observations on EphA4 activation in experimental animal models of TBI and SCI in human brain tissue. First, we showed that EphA4 is expressed on neurons in multiple regions of the intact human brain including cortex and corpus callosum. Second, we showed the expression of EphA4 is markedly upregulated in the brain after TBI and is associated with reactive GFAP-positive astrocytes. Third, we showed that EphA4 is activated as early as 8 hours after the injury and remained in this state for several days. Finally, we demonstrate that EphA4 on human astrocytes can be activated by inflammatory mediators or cl-A5 and that this can be inhibited by unclustered ligand in vitro.
Rapid EphA4 expression upregulation was identified not only at the grossly identified injury site but also in the grossly intact contralateral brain hemisphere. In a previous study using the same patient cohorts, we found that all TBI samples had evidence of diffuse axonal injury with extensive distribution of reactive astrocytes and CD68-positive microglia with no difference between the hemispheres (19) . These results may suggest that EphA4 activation is mediated by inflammatory factors that are increased in the brain due to a generalized inflammatory response after TBI. This hypothesis is reinforced by our in vitro results that EphA4 activation of
FIGURE 2. EphA4 activation in traumatic brain injury (TBI). (A)
Western blot analysis on human brain cortex homogenates at different time points after TBI (n = 4 for control; n = 3 for G17 minutes, n = 2 for up to 2 hours, n = 3 for 92 hours). Phosphorylation of EphA4 (p-EphA4) starts at approximately 8 hours after the injury, whereas only basal levels of EphA4 are detected in the controls and 1 or 2 hours after TBI. EphA4 phosphorylation is detectable in both the ipsilateral (ILH) and the contralateral (CLH) samples. (B) Densitometry analysis shows EphA4 and its p-EphA4 levels normalized against A-actin levels. The graph shows mean T SD of cases grouped by survival times as shown in the human astrocytes is induced by LPS and IFN-F. We also previously showed that EphA4 activation was induced in mouse astrocytes by and here show the same activation mechanisms in human astrocytes. These inflammatory factors induce the expression and secretion of chemokines and proinflammatory cytokines including interleukin-6 and tumor necrosis factor (20, 24, 25) and elicit astrocyte activation (24) . The addition of unclustered ephrin-A5-Fc inhibited the LPS/ IFN-FYinduced increase in EphA4 phosphorylation. In the presence of unclustered ephrinA5, the LPS/IFN-FYinduced morphologic alterations of astrocyte reactivity were ameliorated, suggesting that signaling through the EphA receptors is necessary for the human astrogliotic response. Together, the findings strongly suggest that EphA4 upregulation is an important component of the generalized inflammatory response after TBI (19) .
We observed EphA4 immunoreactivity in cortical neurons and within the corpus callosum. Similar results were observed by Martone et al (22) in 1997 in the adult rat brain. This suggests that EphA4 may have a role in the maintenance of neuronal connections, synaptic formation, and plasticity in the human brain, as suggested for EphA5 (26) . The present data, together with expression data in animal models, indicate that EphA4 expression is highly conserved among mammalian species; this may reflect its important role in brain tissue structure and physiology.
Ephrin/Eph expression and activation are inhibitory for neuronal regeneration after injury, possibly by multiple mechanisms (4) . Eph-ephrin signaling is associated with repulsion signal and stimulates growth cone collapse (6, 27) . EphA receptors and ligands (EphA7, EphA3, EphA4, ephrinA1, and ephrinA3) were found to be upregulated on astrocytes and neurons in the brains of MS patients with active lesions (10) . Because the upregulation of ephrin/Ephs can directly inhibit axonal regeneration by repulsive mechanisms (5), blocking these molecules may be of therapeutic benefit to enhance axonal regeneration after CNS injury. Previously, it was demonstrated that blocking EphA4 with soluble peptide inhibitors was effective in regenerating axons into and through the lesion site, with substantial functional recovery after SCI (28) . In addition, blocking the expression of EphA7 after SCI using antisense oligonucleotides resulted in significant acceleration of hind limb locomotor recovery in rats (13) . A recent study showed that inhibitors of EphA4 kinase significantly inhibited astrocyte proliferation and reactivity in vitro (29) Another approach has been the use of soluble unclustered Ephs and ephrins that function as Eph receptor antagonists (11, 12, 15) . Our recent study showed that using unclustered ephrin-A5-Fc and EphA4-Fc in mice after SCI reduced astrocytic gliosis and improved axonal regeneration through the lesion site (14) . These observations suggest that blocking EphA receptors could ameliorate glial scar formation and enable regenerating axons to enter the lesion site and innervate target cells that survive, or cells in adjacent areas to the lesion, which may improve functional recovery. One of the mechanisms downstream of repulsive guidance molecules, including Eph receptors, is the Rho pathway, which inhibits axonal regeneration (27, 30) . Inhibition of this pathway has also been shown to promote functional recovery after SCI (31Y33). Our results demonstrate that Rho is activated by ephrinA5 in human astrocytes in a similar way to that in mouse astrocytes (6) .
Previously, we showed that cl-A5 inhibited activation of Rho and MAPK pathways through EphA4 in mouse and primate astrocytes (6, 9) . Interestingly, unclustered ephrinA5 managed to block some of the Rho activation that was induced by inflammatory factors such as LPS and IFN-F. This may suggest an unexpected mechanism by which blocking EphA4 reduces the inflammatory response. This is supported by the observation that EphA4 null mice show thymic alterations and T-cell defects (34) . In addition, our experiments demonstrated that inflammation also mediates EphA4 activation, that is, that EphA4 both can be activated as a response to and can mediate the inflammatory response. Because blocking inflammation can promote recovery from SCI through inhibition of the Rho pathway (35, 36) , it is possible that blocking EphA4 may also reduce the inflammatory response after injury and, therefore, promote regeneration.
The MAPK pathway has been shown to be one of the main pathways inducing astrocyte proliferation and differentiation (37, 38) . This pathway is a downstream signal of EphA4, which regulates cortical astrocyte proliferation in vitro (6, 9) . The current study shows for the first time that the Human astrocyte cultures were serum starved for 2 hours (con) before the addition of either clustered ephrinA5-Fc (cl-A5) as a time course or LPS and IFN-F with/without unclustered ephrinA5-Fc (m-A5) for 2 hours. EphA4 activation was examined by immunoprecipitation using anti-phosphotyrosine antibody followed by immunoblotting using anti-EphA4 antibody. Levels of GTP-bound RhoA were determined by a pull-down assay followed by Western blot against RhoA (Rho-GTP). Total RhoA levels were determined by Western blot analysis of whole cell lysates (Rho). Whole cell lysates were analyzed by Western blot using antibodies specific for phosphorylated p42/44 MAPK (p-MAPK) and as total p42/44 MAPK (MAPK). Loading controls were detected by A-actin. (C) Unclustered ligand m-A5 reduced basal levels of EphA4 phosphorylation as well as p-MAPK levels after 2 hours in serum-starved astrocytes. Total EphA4 and MAPK levels were determined from whole cell lysates and remained unchanged for the duration of the experiment. MAPK pathway is activated by EphA4 signaling in human astrocytes and, importantly, that this activation can be reduced in vitro using the unclustered EphA4 ligand; however, unclustered ephrinA5 did not block MAPK activation in the presence of LPS and IFN-F. This may suggest that LPS and IFN-F directly activate the MAPK pathway.
In summary, the present study demonstrates that EphA4 is expressed on neurons in multiple regions of the intact human brain and is markedly upregulated on activated astrocytes after TBI. The inhibition of EphA4 activation and its downstream signaling pathways in human astrocytes supports our hypothesis that blocking these molecules represents a potential therapeutic approach in human brain pathologies including TBI.
